BioAge positive Phase 1 data for BGE-102: 86% hsCRP reduction, 93% normalized

BioAge Labs, Inc.

BGE-102 achieved 86% median hsCRP reduction at Day 14 in obese patients with elevated baseline hsCRP; 93% reached <2 mg/L.
Significant reductions in IL-6 (44%) and fibrinogen (30%) observed, indicating downstream inflammatory cascade suppression.
BGE-102 well tolerated with no dose-limiting toxicities; favorable safety profile.
Phase 1 completion and Phase 2a initiation in obese patients with CV risk factors expected in 1H 2026.
Patent issued covering additional composition of matter and novel NLRP3 binding site.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.